Molecular and Cellular Pharmacology, Vol 9, No 3 (2017)

FDA Approves CAR-T Cell Therapy to Treat Adults With Certain Types of Large B-cell Lymphoma

Abstract

The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma....

Full Text: PDF